Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-29 12:07Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the third quarter of 2025 [2] - As of January 29, 2026, Xinmai Medical's stock closed at 94.72 yuan, with a slight increase of 0.77% and a trading volume of 21,600 shares, resulting in a total transaction amount of 204 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 12.5 million yuan, accounting for 6.11% of the total transaction amount, while retail investors saw a net inflow of 6.98 million yuan, representing 3.41% of the total [1] Group 2 - For the first three quarters of 2025, Xinmai Medical reported a main revenue of 1.015 billion yuan, reflecting a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429 million yuan [2] - The third quarter of 2025 alone saw a significant revenue increase of 64.68% year-on-year, reaching 300 million yuan, although the net profit for that quarter fell by 23.63% to 114 million yuan [2] - The company has a debt ratio of 15.85%, with investment income reported at 11.6 million yuan and a gross profit margin of 70.4% [2]